Citations

Clear

16 citation(s) found for "Skaar, TC".

Economic Evaluation of a Patient-Directed Music Intervention for ICU Patients Receiving Mechanical Ventilatory Support*
Heiderscheit, Annette, Skaar, Debra J. , Neidecker, Marjorie V. , Heiderscheit, Annie , Chlan, Linda L.

Mayo Clinic

Critical Care Medicine | May 4, 2018 | Volume: 46 | Issue: 9 | Pages: 1430-1435

10.1097/ccm.0000000000003199 | PMID 29727366 Get It

Objectives: Music intervention has been shown to reduce anxiety and sedative exposure among mechanically ventilated patients. Whether music intervention reduces ICU costs is not known. The aim of this study was to examine ICU costs for patients receiving a patient-directed music intervention compared with patients who received usual ICU care. Design: A cost-effectiveness analysis from the hospital perspective was conducted to determine if patient-directed music intervention was cost-effective in improving patient-reported anxiety. Cost savings were also evaluated. One-way and probabilistic sensitivity analyses determined the influence of input variation on the cost-effectiveness. Setting: Midwestern ICUs. Patients: Adult ICU patients from a parent clinical trial receiving mechanical ventilatory support. Interventions: Patients receiving the experimental patient-directed music intervention received a MP3 player, noise-canceling headphones, and music tailored to individual preferences by a music therapist. Measurements and Main Results: The base case cost-effectiveness analysis estimated patient-directed music intervention reduced anxiety by 19 points on the Visual Analogue Scale-Anxiety with a reduction in cost of $2,322/patient compared with usual ICU care, resulting in patient-directed music dominance. The probabilistic cost-effectiveness analysis found that average patient-directed music intervention costs were $2,155 less than usual ICU care and projected that cost saving is achieved in 70% of 1,000 iterations. Based on break-even analyses, cost saving is achieved if the per-patient cost of patient-directed music intervention remains below $2,651, a value eight times the base case of $329. Conclusions: Patient-directed music intervention is cost-effective for reducing anxiety in mechanically ventilated ICU patients.
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects
Volpi, Simona , Bult, Carol J. , Chisholm, Rex L. , Deverka, Patricia A. , Jacob, Howard J., Kasapi, Melpomeni , McLeod, Howard L. , Roden, Dan M. , Green, Eric D. , Rodriguez, Laura Lyman , Aronson, Samuel , Cavallari, Larisa H. , Denny, Joshua C. , Dressler, Lynn G., Johnson, Julie A. , Leeder, J. Steven , Piquette‐Miller, Micheline , Rasmussen‐Torvik, Laura J. , Ritchie, Marylyn D. , Skaar, Todd C. , Wagle, Nikhil , Weinshilboum, Richard M. , Weitzel, Kristin, Wildin, Robert S. , Manolio, Teri A. , Relling, Mary V. , Weinshilboum, Richard, Denny, Joshua C , Ginsburg, Geoffrey S. , Roden, Dan M. , Williams, Marc S , Klein, Teri E. , Perera, Minoli A. , Rehm, Heidi L. , Weinshilboum, Richard M. , Wilson, John T. , Cavallari, Larisa H , Rasmussen-Torvik, Laura J

Mayo Clinic

Clinical Pharmacology & Therapeutics | February 21, 2018 | Volume: 103 | Issue: 5 | Pages: 778-786

10.1002/cpt.1048 | PMID 29460415 Get It

Response to a drug often differs widely among individual patients. This variability is frequently observed not only with respect to effective responses but also with adverse drug reactions. Matching patients to the drugs that are most likely to be effective and least likely to cause harm is the goal of effective therapeutics. Pharmacogenomics (PGx) holds the promise of precision medicine through elucidating the genetic determinants responsible for pharmacological outcomes and using them to guide drug selection and dosing. Here we survey the US landscape of research programs in PGx implementation, review current advances and clinical applications of PGx, summarize the obstacles that have hindered PGx implementation, and identify the critical knowledge gaps and possible studies needed to help to address them.
Letting the Patient Decide: A Case Report of Self-Administered Sedation During Mechanical Ventilation
Hetland, Breanna , Hayes, Sarah , Skaar, Debra J. , Tracy, Mary Fran , Weinert, Craig , Hayes, Sarah Maryon, Skaar, Debra, Weinert, Craig R, CHLAN, LINDA, Chlan, Linda L.

Mayo Clinic

Critical Care Nurse | February 1, 2018 | Volume: 38 | Issue: 1 | Pages: 17-23

10.4037/ccn2018676 | PMID 29437074 Get It

It is common for critical care nurses to administer sedative medications to patients receiving mechanical ventilation. Although patient-controlled analgesia is frequently used in practice to promote effective self-management of pain by patients, it is not known if patient-controlled sedation can be used to promote effective self-management of distressing symptoms associated with mechanical ventilation. A randomized pilot trial was conducted to evaluate whether patient self-administered sedation with dexmedetomidine is safe and acceptable for self-management of anxiety during ventilator support. This case report details the experiences of one patient enrolled in the pilot trial who was randomly assigned to the experimental dexmedetomidine intervention, completed the study protocol, and provided feedback. In a poststudy survey, the patient responded positively to the use of self-administered sedation with dexmedetomidine during ventilator support.
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
Hicks, J K, Bishop, JR, Dj, Müller, Leckband, SG, Leeder, JS, Graham, RL, Chiulli, DL, LLerena, Adrián , Skaar, TC, Scott, Stuart A. , Stingl, Julia , Klein, Teri E. , Caudle, KE, Leeder, J. Steven , Müller, Daniel J. , Sangkuhl, Katrin , Ji, Yuan , Skaar, T.C., Gaedigk, Andrea , LLerena, Adrián , Müller, Daniel J , Klein, Teri E , Scott, Stuart A

Mayo Clinic

Clinical Pharmacology & Therapeutics | May 13, 2015 | Volume: 98 | Issue: 2 | Pages: 127-134

10.1002/cpt.147 | PMID 25974703 Get It

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org ).
MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma
Tinder, Teresa L., Basu, Gargi D. , Schettini, Jorge , Arefayene, Million, Skaar, Todd C. , Mukherjee, Pinku , Subramani, Durai B. , Bradley, Judy Martina

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 181 | Issue: 5 | Pages: 3116-3125

10.4049/jimmunol.181.5.3116 | PMID 18713982 Get It

Abstract MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. However, the role of MUC1 in pancreatic cancer has been elusive, partly due to the lack of an appropriate model. We report the characterization of a novel mouse model that expresses human MUC1 as a self molecule (PDA.MUC1 mice). Pancreatic tumors arise in an appropriate MUC1-tolerant background within an immune-competent host. Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation. Tumors from PDA.MUC1 mice express higher levels of cyclooxygenase-2 and IDO compared with PDA mice lacking MUC1, especially during early stages of tumor development. The increased proinflammatory milieu correlates with an increased percentage of regulatory T cells and myeloid suppressor cells in the pancreatic tumor and tumor draining lymph nodes. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses. Thus, the mouse model is ideally suited for testing novel chemopreventive and therapeutic strategies against pancreatic cancer.
Progression of Pancreatic Adenocarcinoma Is Significantly Impeded with a Combination of Vaccine and COX-2 Inhibition
Mukherjee, Pinku , Basu, Gargi D. , Tinder, Teresa L., Arefayene, Million, Skaar, Todd C. , Subramani, Durai B. , Bradley, Judy Martina , Petris, Giovanni De

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 182 | Issue: 1 | Pages: 216-224

10.4049/jimmunol.182.1.216 Get It

Abstract With a 5-year survival rate of <5%, pancreatic cancer is one of the most rapidly fatal malignancies. Current protocols for the treatment of pancreas cancer are not as effective as we desire. In this study, we show that a novel Mucin-1 (MUC1)-based vaccine in combination with a cyclooxygenase-2 inhibitor (celecoxib), and low-dose chemotherapy (gemcitabine) was effective in preventing the progression of preneoplastic intraepithelial lesions to invasive pancreatic ductal adenocarcinomas. The study was conducted in an appropriate triple transgenic model of spontaneous pancreatic cancer induced by the KRASG12D mutation and that expresses human MUC1 as a self molecule. The combination treatment elicited robust antitumor cellular and humoral immune responses and was associated with increased apoptosis in the tumor. The mechanism for the increased immune response was attributed to the down-regulation of circulating prostaglandin E2 and indoleamine 2, 3,-dioxygenase enzymatic activity, as well as decreased levels of T regulatory and myeloid suppressor cells within the tumor microenvironment. The preclinical data provide the rationale to design clinical trials with a combination of MUC1-based vaccine, celecoxib, and gemcitabine for the treatment of pancreatic cancer.